gm.cd40l.ccl21
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2012 (NCT01433172)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD40-CD40LImmunity, active
CD40-CD40L immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gm.cd40l.ccl21
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01433172 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2012 | Bankhead-Coley Florida Biomedical Research Program, James and Esther King Biomedical Research Program, University of South Florida |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bankhead-Coley Florida Biomedical Research Program | Government | 1 | 0 | 1 | 2012 |
| James and Esther King Biomedical Research Program | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2012 |
3 organizations
Page 1 / 1